Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon betaDaniel Wynn, John Rose, Alice Fong et al.|The Lancet Neurology|2010Cited by 300
Daclizumab phase II trial in relapsing and remitting multiple sclerosisJohn Rose, Noel G. Carlson, JaneC Burns et al.|Neurology|2007Cited by 161
Cyclooxygenase-2 expression in oligodendrocytes increases sensitivity to excitotoxic deathNoel G. Carlson, John Rose|Journal of Neuroinflammation|2010Cited by 40
Open-label, add-on trial of cetirizine for neuromyelitis opticaIlana Katz Sand, Fred Lublin, Thomas M. Moran et al.|Neurology Neuroimmunology & Neuroinflammation|2018Cited by 26